Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cancer Active
Lund, Swedencanceractive.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tasquinimod is in clinical phase Ib/IIa for myelofibrosis and multiple myeloma; Laquinimod has completed phase I for inflammatory eye disorders with ongoing biodistribution study; Naptumomab (licensed to NeoTX) is in phase Ib/II for solid tumors[2][6]
- Therapeutic areas
- OncologyOphthalmologyNeurology
- Modalities
- Small molecules (orally active immunomodulatory molecules)Antibody-based immunotherapyTumor-targeting superantigen (TTS)
- Industry
- Biotech
02
Partnerships
NeoTX Therapeutics Ltd (for Naptumomab/Anyara)AstraZeneca/MedImmune (clinical collaboration with NeoTX for Anyara)
Beyond the preview
Go deeper on Cancer Active.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cancer Active.